LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma
Future Oncology · 2023-12 · 19 (40) · 2631-2640
DOI: 10.2217/fon-2023-0283 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Future Oncology, online erschienen am 26.10.2023. Verfasst von Toni K Choueiri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Antineoplastic Agents, Kidney Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and NIH 5P30CA008748-56 MSK Cancer Center Support Grant (MH Voss), Merck Sharp & Dohme LLC.
Abstract (Originalsprache)
Combination treatment with immunotherapy agents and/or vascular endothelial growth factor tyrosine kinase inhibitors are a standard of care for patients with advanced clear cell renal cell carcinoma (ccRCC). Novel therapeutic combinations that include the hypoxia-inducible factor 2α inhibitor belzutifan and the cytotoxic T-lymphocyte-associated protein 4 inhibitor quavonlimab are being investigated for their potential to further improve patient outcomes. This protocol describes the rationale and design of the randomized, phase III LITESPARK-012 study, which will evaluate the efficacy and safety of pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab as first-line treatment for advanced ccRCC. Results from this study may support triplet combination therapies as a potential new standard of care for advanced ccRCC. Clinical trial registry: NCT04736706 (ClinicalTrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.
- Barts Health NHS Trust & the Royal Free NHS Foundation Trust, Barts Cancer Institute, Queen Mary University of London, London, UK.
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Fox Chase Cancer Center, Philadelphia, PA, USA.
- Westmead Hospital, Sydney, NSW, Australia.
- Macquarie University Hospital, Sydney, NSW, Australia.
ORCID-Profile: Toni K Choueiri
Förderung
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and NIH 5P30CA008748-56 MSK Cancer Center Support Grant (MH Voss)
- Merck Sharp & Dohme LLC
Zitieren
APA
Choueiri, T. K., Powles, T., Voss, M. H., Plimack, E. R., Gurney, H., Song, Y., Perini, R. F., Rodriguez-Lopez, K., & Rini, B. I. (2023). LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma. Future Oncology, 19(40), 2631-2640. https://doi.org/10.2217/fon-2023-0283
Vancouver
Choueiri TK, Powles T, Voss MH, Plimack ER, Gurney H, Song Y, et al. LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma. Future Oncology. 2023;19(40):2631-2640. doi:10.2217/fon-2023-0283
BibTeX
@article{Choueiri2023,
author = {Choueiri, Toni K and Powles, Thomas and Voss, Martin H and Plimack, Elizabeth R and Gurney, Howard and Song, Yue and Perini, Rodolfo F and Rodriguez-Lopez, Karla and Rini, Brian I},
title = {LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma},
journal = {Future Oncology},
year = {2023},
volume = {19},
number = {40},
pages = {2631--2640},
doi = {10.2217/fon-2023-0283}
}
EUVIMED